Mina C. Hosseinipour
University of North Carolina at Chapel Hill
378 Papers
1.7K Citations
Mina C. Hosseinipour is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 48, co-authored 333 publications. Previous affiliations of Mina C. Hosseinipour include University of Malawi & Kamuzu Central Hospital.
Chat about Author
Papers
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial
Mina C. Hosseinipour,Minhee Kang,Susan E. Krown,Aggrey Bukuru,Triin Umbleja,Jeffrey N. Martin,Jackson Orem,Catherine Godfrey,Brenda Hoagland,Noluthando Mwelase,Deborah Langat,Mulinda Nyirenda,John MacRae,Margaret Borok,Wadzanai Samaneka,Agnes Moses,Rosie Mngqbisa,Naftali Busakhala,Otoniel Martinez-Maza,Richard F. Ambinder,Dirk P. Dittmer,Mostafa Nokta,Thomas B. Campbell,Amc React-Ks Team +23 more
TL;DR: Among HIV-infected adults with mild-to-moderate KS, immediate ET provided early, nondurable clinical benefits, but by 48 weeks, no clinical benefit was observed compared to use of ET as needed.
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Mina C. Hosseinipour,Amanda H Corbett,Cecelia Kanyama,Idah Mshali,Severiano Phakati,Nazer L. Rezk,Charles van der Horst,Angela D. M. Kashuba +7 more
TL;DR: Although exposures were similar, Triomune did not meet the strict definition of bioequivalence for these drugs and Malawians had higher nevirapine exposures compared with historical reports of Western HIV-infected patients.
31
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Mina C. Hosseinipour,Craig Innes,Sarita Naidoo,Philipp Mann,Julia Hutter,Gita Ramjee,Sebe M,Lucas Maganga,Michael E Herce,Allan C. deCamp,Kyle E. Marshall,One Dintwe,Erica Andersen-Nissen,Georgia D. Tomaras,Nonhlanhla N. Mkhize,Lynn Morris,Ryan L. Jensen,Miner,Giuseppe Pantaleo,S. Ding,Van Der Meeren O,Susan W. Barnett,MJ McElrath,Lawrence Corey,James G. Kublin +24 more
TL;DR: Both the prime/boost and coadministration regimens are safe and may be promising for advancement into efficacy trials depending on whether cellular or humoral responses are desired.
Brief Report: Impact of Option B+ on the Infant PMTCT Cascade in Lilongwe, Malawi.
Maria H. Kim,Maria H. Kim,Saeed Ahmed,Saeed Ahmed,Mina C. Hosseinipour,Xiaoying Yu,Chi Nguyen,Frank Chimbwandira,Mary E. Paul,Peter N. Kazembe,Elaine J. Abrams +10 more
TL;DR: Comparing uptake of infant prevention of mother-to-child transmission of HIV services pre/post implementation of Option B+ in Lilongwe, Malawi suggests modest improvements in infant care with Option B+.
30
Sexual partnership patterns in malawi: implications for HIV/STI transmission.
Kimberly A. Powers,Irving F. Hoffman,Azra C. Ghani,Mina C. Hosseinipour,Christopher D. Pilcher,Matthew Price,Audrey Pettifor,David Chilongozi,Francis Martinson,Myron S. Cohen,William C. Miller +10 more
TL;DR: Among those reporting multiple recent partners, both long-term concurrency and narrowly spaced consecutive partnerships could present substantial risk for efficient transmission of HIV and classical STIs.
29